{"denoms":[{"counts":[{"groupId":"BG000","value":"327"},{"groupId":"BG001","value":"322"},{"groupId":"BG002","value":"649"}],"units":"Participants"}],"groups":[{"description":"Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"BG000","title":"Bevacizumab + IFN-Alfa-2A"},{"description":"Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"BG001","title":"Placebo + IFN-Alfa-2A"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.12","value":"60.1"},{"groupId":"BG001","spread":"10.89","value":"59.4"},{"groupId":"BG002","spread":"10.51","value":"59.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"105"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"192"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"222"},{"groupId":"BG001","value":"235"},{"groupId":"BG002","value":"457"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-treat population (ITT) included all participants randomized into the study."}